Anacor Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. The Company has discovered, synthesized and developed seven molecules that are in development. Its lead product candidates include two topically administered dermatologic compounds tavaborole and AN2728. In addition, the Company has discovered three compounds that it has out-licensed for further developmentGSK2251052 (GSK '052), AN8194 and AN5568. The Company's clinical pipeline also includes two additional product candidates. AN2718, its second topical antifungal product candidate, has the potential to treat onychomycosis and fungal infections of the skin. AN2898, the Company's second topical anti-inflammatory product candidate, has the potential to treat atopic dermatitis and psoriasis.